NCBI PubMed Central
open access
The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Systems serology of responses against tumor antigens in ovarian cancer reveal disrupted Fc-mediated immunity#234314
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer#184945
- Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer#833262
- Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients#1102553
- Immunotherapy does not impair ovarian function in a mouse model of breast cancer.#378512
Record · ID 653460
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive